Highlights from ASCO 2017 Annual Meeting
ASCO 2017 Prostate Cancer
- ASCO 2017: Does Prostate Cancer Presentation and Biologic Characteristics Differ in Older Patients?
- ASCO 2017: How Randomized Trials of STAMPEDE Have Influenced Treatment Decisions in the United Kingdom
- ASCO 2017: Physical and Cognitive Effects of Systemic Therapy in Older Men with Prostate Cancer
- ASCO 2017: Key Interdisciplinary and Integrated Treatment Planning Necessary to Effectively Treat Older Adults With Prostate Cancer
- ASCO 2017: How Advances in Molecular Imaging Have Changed Our Understanding of State and Stage of the Disease
ASCO 2017 Bladder Cancer
- ASCO 2017: Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer
- ASCO 2017: The clinical role of purified protein derivative skin test reaction in patients with non-muscle invasive bladder cancer treated with bacillus-Calmette Guerin
- ASCO 2017: Cabazitaxel in patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy: Results of a phase II trial—CAB-B1.
- ASCO 2017: Effectiveness of the Moreau strain of Bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer
- ASCO 2017: Survival outcomes in elderly patients with muscle invasive bladder cancer: An analysis of the National Cancer Database
ASCO 2017 Renal Cancer
- ASCO 2017: Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients
- ASCO 2017: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)
- ASCO 2017: Can Subgroup Analyses Identify Enrichment Strategies for Adjuvant RCC Studies?
- ASCO 2017: Emerging VEGF-I/O Combinations: Efficacy and Toxicity
- ASCO 2017: A phase I/II study to assess the safety and efficacy of pazopanib and pembrolizumab in patients with advanced renal cell carcinoma
ASCO 2017 Penile Cancer
ASCO 2017 Testicular Cancer
- ASCO 2017: The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer
- ASCO 2017: Taking Us Out of the Refractory State: Combination Chemotherapy to Immunotherapy for Refractory Germ Cell Tumors
- ASCO 2017: Long-term causes of relative excess mortality after diagnosis of testicular germ cell tumor
- ASCO 2017: Safety and usefulness of patient-centered shared survivorship care after chemotherapy for testicular cancer
- ASCO 2017: FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry
ASCO 2017 Adrenocortical Cancer
ASCO 2017 Press Releases
- ASCO 2017: New Technology Dives Deep Into the Cancer Genome- An Initial Step Toward Blood Tests for Early Detection of Cancer
- ASCO 2017: Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival
- ASCO 2017: Abiraterone Slows Advanced Prostate Cancer, Helps Patients Live Longer
- ASCO 2017: World’s Largest Clinical Cancer Research Meeting to Highlight Latest Advances in Patient and Survivor Care
- ASCO 2017: Steady Decrease in Severe Health Problems for Childhood Cancer Survivors